Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
METHODS
It is well known that deferoxamine (DFO) treatment in thalassemia major can produce ocular toxicity. In one experience, Visual evoked potentials (VEPS) to pattern reversal were formed to be altered in 4 out of 10 patients under conventional treatment with DFO, before supplementary high-dose i.v. deferoxamine. In all 4 cases the alterations consisted of bilaterally delayed P100 latency, always obtained by stimulation with high spatial frequency (15' checks) and associated in three cases with low spatial frequency (55'). Computerized EEG (cEEG) studies showed a generalized increase of slowing activity. All patients underwent high-dose DFO treatment.


RESULTS
At the control performed at the end of treatment in all 4 cases with previous VEP alterations, a further delay in P100 latency was observed bilaterally while two of the six patients, without previous involvement, showed delayed responses when using checks of 15'. The EEG slowing activity was not modified. Three weeks after terminating i.v. DFO therapy, the patients were still under subcutaneous treatment (50 mg/kg/day); a more evident VEP recovery towards the initial values was observed in those patients without initial alterations. No significant changes were found between electrophysiological parameters and serum ferritin levels.


CONCLUSIONS
Our results indicate that high-dose DFO therapy in patients with iron overload induces reversible visual impairment without significant changes in brain electrical activity. The employment of VEP in intensive chelation programs in thalassemia major is discussed.
Clinica Neurologica, II Università Tor Vergata, Roma, Italy.
M G
MG
Marciani
P
P
Cianciulli
N
N
Stefani
F
F
Stefanini
L
L
Peroni
M
M
Sabbadini
M
M
Maschio
G
G
Trua
G
G
Papa
D000293:Adolescent; D000328:Adult; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D015913:Chelation Therapy / Q000009:adverse effects; D002648:Child; D003676:Deferoxamine / Q000009:adverse effects* / Q000627:therapeutic use; D004569:Electroencephalography / Q000187:drug effects*; D004594:Electrophysiology; D005074:Evoked Potentials, Visual / Q000187:drug effects*; D005260:Female; D005293:Ferritins / Q000032:analysis; D006432:Hemochromatosis / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007501:Iron; D008297:Male; D013789:Thalassemia / Q000628:therapy*; D065227:Transfusion Reaction
D005293:Ferritins; D007501:Iron; D003676:Deferoxamine